New York, NY — August 11, 2026 — Researchers at the Icahn School of Medicine at Mount Sinai have advanced to the finals of XPRIZE Healthspan, a $101 million global competition seeking therapies that can extend the years people live in good health. The Mount Sinai team, known as NYC-Vita, has received a $1 million Milestone 2 award after being selected from an international field of semifinalists. Its work focuses on improving immune function and identifying biological changes that could help older adults maintain strength, cognition, independence, and resistance to disease.
XPRIZE Healthspan is a seven-year competition designed to push aging research beyond incremental improvements. Participating teams are developing and testing interventions intended to restore muscle, cognitive, and immune performance in adults between 50 and 90 years of age. The competition defines success as producing measurable improvements equivalent to at least 10 years of healthier function—and potentially as much as 20 years—within one year or less of treatment. The goal is not simply to increase lifespan, but to delay or reverse functional decline while people remain active and independent.
The NYC-Vita team is conducting a clinical trial that combines lifestyle and pharmaceutical interventions to examine whether immune-system performance can be improved during aging. The study reflects a growing scientific consensus that aging is not governed by a single mechanism. Instead, it emerges from interconnected changes involving chronic inflammation, metabolic dysfunction, impaired tissue repair, altered immune-cell behavior, vascular damage, and declining neurological resilience. By measuring these processes together, the researchers hope to determine whether targeted interventions can produce broad improvements in healthspan rather than isolated changes in one organ.
A central scientific focus of the program is the aging immune system, a process known as immunosenescence. With age, immune cells may become less responsive to new infections and vaccines, while other immune populations can remain persistently activated and promote low-grade inflammation. This chronic inflammatory state, sometimes called inflammaging, has been associated with cardiovascular disease, neurodegeneration, frailty, metabolic disorders, and reduced ability to recover from illness. NYC-Vita is designed to investigate whether pharmaceutical and behavioral strategies can shift the immune system toward a more balanced and effective state.
The Mount Sinai effort brings together specialists in immunology, neuroscience, metabolism, medical imaging, wearable technology, and clinical investigation. Miriam Merad, MD, PhD, leads the NYC-Vita team and is internationally recognized for her research on macrophages, immune cells that regulate inflammation, tissue repair, and responses to disease. The team also includes Zahi Fayad, PhD, whose work uses advanced imaging and wearable technologies to study biological and lifestyle stressors; Fanny Elahi, MD, PhD, an expert in neurodegeneration and brain health; Thomas Marron, MD, PhD, principal investigator of the NYC-Vita clinical trial; and Ryan W. Walker, PhD, MS, whose research examines metabolic and nutritional influences on healthy aging.
For the study, the researchers are expected to evaluate healthspan using multiple biological and functional measures rather than relying on chronological age alone. Such assessments can include immune-cell profiles, inflammatory markers, metabolic measurements, neurocognitive testing, physical-performance data, and imaging-based indicators of tissue health. Wearable devices may provide continuous information about activity, sleep, heart-rate patterns, and other behavioral signals. Combining these data streams could help researchers identify whether an intervention produces a coordinated improvement across systems or merely changes a laboratory measurement without meaningful benefits in daily life.
“Advancing to the finals of this highly competitive global initiative reflects the exceptional scientific foundation we have built at Mount Sinai and the strength of our collaborative research enterprise,” said Eric J. Nestler, MD, PhD, Anne and Joel Ehrenkranz Dean of the Icahn School of Medicine at Mount Sinai and Executive Vice President of the Mount Sinai Health System. He said the collaboration across immunology, neuroscience, metabolism, imaging, and clinical research could help redefine how healthy aging is understood and promoted.
Merad said the team’s selection as a finalist recognizes both the promise of its scientific strategy and the work of its multidisciplinary researchers. The $1 million award will support the continued development of NYC-Vita and help accelerate investigations into interventions that may preserve physical strength, independence, and quality of life. The program is part of Mount Sinai’s broader Healthspan Program, which links biomedical research with clinical care and aims to translate discoveries about aging into practical approaches for preventing or delaying age-related disease.
XPRIZE announced 20 finalist teams at an awards ceremony in Salt Lake City. Ten of those teams, including Mount Sinai, were selected as Milestone 2 Awardees and will share $10 million in direct milestone funding, with each receiving $1 million. Awardees will also gain access to clinical testing resources intended to speed the evaluation of their therapeutic approaches. The finalists represent the United States, South Korea, Japan, and China, underscoring the international competition surrounding efforts to alter the biology of aging. The contest is scheduled to culminate in 2030, when XPRIZE plans to award a grand prize of up to $81 million. Mount Sinai leaders said the team will continue the NYC-Vita trial while seeking additional collaborators and philanthropic support to expand the research and determine whether improvements in immune health can translate into longer, healthier lives.
Subject of Research: Healthy aging, immune-system function, immunosenescence, inflammaging, and interventions designed to extend healthspan.
Article Title: Mount Sinai Team Advances to XPRIZE Healthspan Finals With Immune-Aging Clinical Trial
News Publication Date: August 11, 2026
Web References:
https://www.mountsinai.org/about/healthspan/research
https://profiles.mountsinai.org/miriam-merad
https://profiles.mountsinai.org/zahi-a-fayad
https://profiles.mountsinai.org/fanny-m-elahi
https://profiles.mountsinai.org/thomas-u-marron
https://profiles.icahn.mssm.edu/ryan-w-walker
https://www.mountsinai.org/about/executive-leadership/nestler
https://www.mountsinai.org/about/executive-leadership/brendan-carr
References: XPRIZE Healthspan competition announcement; Icahn School of Medicine at Mount Sinai NYC-Vita clinical trial and Healthspan Program information.
Keywords: healthy aging, healthspan, XPRIZE Healthspan, NYC-Vita, immune aging, immunosenescence, inflammaging, macrophages, clinical trial, Mount Sinai, longevity research, age-related disease, medical imaging, wearable technology, neuroscience, metabolism
Tags: Agingaging and independence preservationaging intervention clinical trialsbiological markers of agingcognitive and physical health in older adultsHealthspan Extensionimmune system rejuvenationinnovative therapies for healthy aginginternational aging research collaborationslongevity researchMount Sinai researchXPRIZE Healthspan competition
